Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, Kiessling R.

Cancer Res. 2006 Jun 15;66(12):6387-94.

2.

Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.

Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ.

J Immunol. 1994 Mar 1;152(5):2393-400.

PMID:
8133050
3.

Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.

Sotiropoulou PA, Perez SA, Voelter V, Echner H, Missitzis I, Tsavaris NB, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2003 Dec;52(12):771-9. Epub 2003 Sep 10.

PMID:
13680193
4.
5.

Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.

Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ.

J Immunol. 1995 Nov 1;155(9):4486-91.

PMID:
7594611
6.

HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.

Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R.

Cancer Immunol Immunother. 2009 May;58(5):653-64. doi: 10.1007/s00262-008-0587-1. Epub 2008 Sep 27.

PMID:
18820911
7.

Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.

Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Cancer. 2009 Feb 15;115(4):800-11. doi: 10.1002/cncr.24048.

8.

TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.

Peoples GE, Yoshino I, Douville CC, Andrews JV, Goedegebuure PS, Eberlein TJ.

J Immunol. 1994 May 15;152(10):4993-9.

PMID:
7909829
9.

Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.

Goedegebuure PS, Douville CC, Doherty JM, Linehan DC, Lee KY, Ganguly EK, Eberlein TJ.

Cell Immunol. 1997 Feb 1;175(2):150-6.

PMID:
9023420
10.

Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.

Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanovi├ž S, Wallwiener D, G├╝ckel B.

Clin Cancer Res. 2003 Oct 1;9(12):4376-86.

11.

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C.

Cancer Res. 2000 Sep 1;60(17):4850-4.

12.

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ.

Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):432-6.

13.

HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.

Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ.

Cancer Res. 1994 Jul 1;54(13):3387-90.

14.

Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.

Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y.

Clin Cancer Res. 2002 Nov;8(11):3394-400.

15.

Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.

Kaplan BL, Norell H, Callender GG, Ohlum T, Kiessling R, Nishimura MI.

Cancer Immunol Immunother. 2006 Jun;55(6):653-62. Epub 2005 Sep 6.

PMID:
16151808
16.
17.

Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.

Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN.

J Immunol. 2008 Jul 1;181(1):146-54.

18.

Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing.

Weidanz JA, Nguyen T, Woodburn T, Neethling FA, Chiriva-Internati M, Hildebrand WH, Lustgarten J.

J Immunol. 2006 Oct 15;177(8):5088-97.

19.

Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.

Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV.

Gynecol Oncol. 2006 Oct;103(1):145-50. Epub 2006 Mar 20.

PMID:
16542716
20.

Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer.

Yamada A, Kawano K, Harashima N, Niiya F, Nagai K, Kobayashi T, Mine T, Ushijima K, Nishida T, Itoh K.

Cancer Immunol Immunother. 1999 May-Jun;48(2-3):147-52.

PMID:
10414469
Items per page

Supplemental Content

Write to the Help Desk